Hypertension Related Damage to the Microcirculation in South Asian: Emergence, Predictive Power and Reversibility

NCT ID: NCT00331370

Last Updated: 2006-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

2880 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Damage to very small blood vessels is a consequence, but can also precede high blood pressure. Such damage, measured by disturbances in the vessels in the retina (back of the eye) is a strong predictor of heart disease and stroke. South Asian people have one of the highest rates of hypertension in the world (30% in adults). In Pakistan, this is usually severe, undetected and untreated. The Wellcome Trust has already funded a study of blood pressure control in adults and children in this population. We propose a substudy, taking photographs of the retina and making measurements of the vessels, to determine whether such blood pressure related changes occur at an early age in young children with a family history of high blood pressure compared to those without, whether such changes predict an increase in blood pressure over time, and whether, in adults, such changes can be reversed by blood pressure treatment. The hypothesis of our study is: young offspring of South Asian people with hypertension have a disturbed microcirculation, as assessed by abnormalities of retinal vessels, compared to offspring of normotensive parents. Our 2nd hypothesis is: Abnormal retinal vascular geometry will improve proportionately to achieved reductions in BP.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background

The role of the microcirculation is increasingly being recognized in the etiopathogenesis of cardiovascular disease. Delays in this recognition are in part due to the difficulty of studying the microcirculation non-invasively, in large numbers of individuals. Retinal vessels provide an easily accessible "window" to the microcirculation. Abnormalities of the retinal vasculature have been shown to be associated with cardiovascular risk factors and all cause mortality. Non-invasive assessment of the retinal circulation presents a valuable opportunity to study the structure and function of the microvasculature

Aims of the project

To compare geometry of retinal microvasculature of 1) hypertensive vs normotensive adults, 2) children aged 10 to 14 years of hypertensive parent (test group) versus normotensive parent (control group), and, 3) to assess the impact of blood pressure lowering on these changes over 2 years.

Primary outcome would be abnormal retinal geometry defined as the composite outcome of a) abnormal arteriolar length: diameter ratios (a measure of relative arteriolar narrowing), b) narrowed branching angles (an indicator of arteriolar rarefaction), or c) disturbed junction exponents (a marker of endothelial dysfunction.

Significance of the study

If successful, this work could be extended to address future questions, including the predictive value of these abnormalities for development of diabetes and hypertension as well as CVD; to explore further the role of microvascular disturbances in disease etiology, and to assess the impact of drug therapy on these abnormalities and their relationship to outcomes in the South Asian population

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Diabetes Cardiovascular Disease Retinopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GP training and Health Education

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All subjects aged 9 years or over residing in randomly selected communities

Exclusion Criteria

Pregnancy

Those who have severe co-morbid conditions

Patients with known history of glaucoma will be excluded from our study because instillation of mydriatic drops was thought to be hazardous for them.
Minimum Eligible Age

9 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Imperial College London

OTHER

Sponsor Role collaborator

Aga Khan University

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tazeen H Jafar, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Aga Khan University

Nish Chaturvedi, MD, MFPHM

Role: STUDY_CHAIR

Imperial College London

Alun Hughes, MD, Phd

Role: STUDY_CHAIR

Imperial College London

Juanita Hatcher, Phd, MSc

Role: STUDY_CHAIR

Aga Khan University

Simon Thom, MD, FRCP

Role: STUDY_CHAIR

Imperial College London

Khabir Ahmad, MD, MSc

Role: STUDY_CHAIR

Aga Khan University

Muhammad Saleem Khan, MSc Epi&Bio

Role: STUDY_CHAIR

Aga Khan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aga Khan University

Karachi, Sindh, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tazeen H Jafar, Md,MPH

Role: CONTACT

Phone: 0092-4930051

Email: [email protected]

Muhamamd Saleem Khan, MSc Epi&Bio

Role: CONTACT

Phone: 0092-4930051

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tazeen H Jafar, MD, MPH

Role: primary

Muhammad Saleem Khan, MSc Epi&Bio

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DHCPP00493

Identifier Type: -

Identifier Source: org_study_id